300 related articles for article (PubMed ID: 32747394)
21. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY
Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331
[TBL] [Abstract][Full Text] [Related]
23. rAAV-CFTRΔR Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and Cystic Fibrosis Mice.
Vidović D; Carlon MS; da Cunha MF; Dekkers JF; Hollenhorst MI; Bijvelds MJ; Ramalho AS; Van den Haute C; Ferrante M; Baekelandt V; Janssens HM; De Boeck K; Sermet-Gaudelus I; de Jonge HR; Gijsbers R; Beekman JM; Edelman A; Debyser Z
Am J Respir Crit Care Med; 2016 Feb; 193(3):288-98. PubMed ID: 26509335
[TBL] [Abstract][Full Text] [Related]
24. R117H-CFTR function and response to VX-770 correlate with mRNA and protein expression in intestinal organoids.
Van Mourik P; van Haaren P; Kruisselbrink E; Korkmaz C; Janssens HM; de Winter-de Groot KM; van der Ent CK; Hagemeijer MC; Beekman JM
J Cyst Fibros; 2020 Sep; 19(5):728-732. PubMed ID: 32061518
[TBL] [Abstract][Full Text] [Related]
25. Health Characteristics of Patients with Cystic Fibrosis whose Genotype Includes a Variant of the Nucleotide Sequence c.3140-16T>A and Functional Analysis of this Variant.
Kondratyeva E; Bukharova T; Efremova A; Melyanovskaya Y; Bulatenko N; Davydenko K; Filatova A; Skoblov M; Krasovsky S; Petrova N; Polyakov A; Adyan T; Amelina E; Shadrina V; Zhekaite E; Zodbinova A; Chernyak A; Zinchenko R; Kutsev S; Goldshtein D
Genes (Basel); 2021 May; 12(6):. PubMed ID: 34071719
[TBL] [Abstract][Full Text] [Related]
26. The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: a basis for read-through therapies in cystic fibrosis.
Clarke LA; Awatade NT; Felício VM; Silva IA; Calucho M; Pereira L; Azevedo P; Cavaco J; Barreto C; Bertuzzo C; Gartner S; Beekman J; Amaral MD
Hum Mutat; 2019 Mar; 40(3):326-334. PubMed ID: 30488522
[TBL] [Abstract][Full Text] [Related]
27. A functional CFTR assay using primary cystic fibrosis intestinal organoids.
Dekkers JF; Wiegerinck CL; de Jonge HR; Bronsveld I; Janssens HM; de Winter-de Groot KM; Brandsma AM; de Jong NW; Bijvelds MJ; Scholte BJ; Nieuwenhuis EE; van den Brink S; Clevers H; van der Ent CK; Middendorp S; Beekman JM
Nat Med; 2013 Jul; 19(7):939-45. PubMed ID: 23727931
[TBL] [Abstract][Full Text] [Related]
28. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
[TBL] [Abstract][Full Text] [Related]
29. Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis.
McCague AF; Raraigh KS; Pellicore MJ; Davis-Marcisak EF; Evans TA; Han ST; Lu Z; Joynt AT; Sharma N; Castellani C; Collaco JM; Corey M; Lewis MH; Penland CM; Rommens JM; Stephenson AL; Sosnay PR; Cutting GR
Am J Respir Crit Care Med; 2019 May; 199(9):1116-1126. PubMed ID: 30888834
[No Abstract] [Full Text] [Related]
30. Evaluation of the Complex p.[Leu467Phe;Phe508del] CFTR Allele in the Intestinal Organoids Model: Implications for Therapy.
Kondratyeva E; Efremova A; Melyanovskaya Y; Voronkova A; Polyakov A; Bulatenko N; Adyan T; Sherman V; Kovalskaia V; Petrova N; Starinova M; Bukharova T; Kutsev S; Goldshtein D
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142302
[TBL] [Abstract][Full Text] [Related]
31. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
32. Rectal organoid morphology analysis (ROMA) as a promising diagnostic tool in cystic fibrosis.
Cuyx S; Ramalho AS; Corthout N; Fieuws S; Fürstová E; Arnauts K; Ferrante M; Verfaillie C; Munck S; Boon M; Proesmans M; Dupont L; De Boeck K; Vermeulen F;
Thorax; 2021 Nov; 76(11):1146-1149. PubMed ID: 33859053
[TBL] [Abstract][Full Text] [Related]
33. Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function.
de Winter-de Groot KM; Janssens HM; van Uum RT; Dekkers JF; Berkers G; Vonk A; Kruisselbrink E; Oppelaar H; Vries R; Clevers H; Houwen RHJ; Escher JC; Elias SG; de Jonge HR; de Rijke YB; Tiddens HAWM; van der Ent CK; Beekman JM
Eur Respir J; 2018 Sep; 52(3):. PubMed ID: 30166324
[TBL] [Abstract][Full Text] [Related]
34. L1077P CFTR pathogenic variant function rescue by Elexacaftor-Tezacaftor-Ivacaftor in cystic fibrosis patient-derived air-liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients.
Lo Cicero S; Castelli G; Blaconà G; Bruno SM; Sette G; Pigliucci R; Villella VR; Esposito S; Zollo I; Spadaro F; Maria R; Biffoni M; Cimino G; Amato F; Lucarelli M; Eramo A
Respir Res; 2023 Sep; 24(1):217. PubMed ID: 37674160
[TBL] [Abstract][Full Text] [Related]
35. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
Cuyx S; De Boeck K
Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
[TBL] [Abstract][Full Text] [Related]
36. Targeted locus amplification reveals heterogeneity between and within CFTR genotypes and association with CFTR function in patient-derived intestinal organoids.
Lefferts JW; Boersma V; Nieuwenhuijze NDA; Suen SWF; Hajo K; Collantes NS; Vermeulen C; Groeneweg T; Hagemeijer MC; de Jonge HR; van der Ent CK; Splinter E; Beekman JM
J Cyst Fibros; 2023 May; 22(3):538-547. PubMed ID: 37100706
[TBL] [Abstract][Full Text] [Related]
37. Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids.
Crawford DK; Mullenders J; Pott J; Boj SF; Landskroner-Eiger S; Goddeeris MM
J Cyst Fibros; 2021 May; 20(3):436-442. PubMed ID: 33558100
[TBL] [Abstract][Full Text] [Related]
38. CFTR function is impaired in a subset of patients with pancreatitis carrying rare CFTR variants.
Angyal D; Kleinfelder K; Ciciriello F; Groeneweg TA; De Marchi G; de Pretis N; Bernardoni L; Rodella L; Tomba F; De Angelis P; Surace C; Pintani E; Alghisi F; de Jonge HR; Melotti P; Sorio C; Lucidi V; Bijvelds MJC; Frulloni L
Pancreatology; 2024 May; 24(3):394-403. PubMed ID: 38493004
[TBL] [Abstract][Full Text] [Related]
39. Theratyping of the Rare CFTR Genotype A559T in Rectal Organoids and Nasal Cells Reveals a Relevant Response to Elexacaftor (VX-445) and Tezacaftor (VX-661) Combination.
Kleinfelder K; Villella VR; Hristodor AM; Laudanna C; Castaldo G; Amato F; Melotti P; Sorio C
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373505
[TBL] [Abstract][Full Text] [Related]
40. Rectal organoid-guided CFTR modulator therapy restores lung function in a cystic fibrosis patient with the rare 1677delTA/R334W genotype.
Mitropoulou G; Brandenberg N; Hoehnel S; Ceroni C; Balmpouzis Z; Blanchon S; Dorta G; Sauty A; Koutsokera A
Eur Respir J; 2022 Dec; 60(6):. PubMed ID: 36423906
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
